Drug Type Small molecule drug |
Synonyms AI, AZLI, aztreonam + [5] |
Target |
Mechanism PBPs inhibitors(Bacterial penicillin-binding protein inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date EU (21 Sep 2009), |
Regulation- |
Molecular FormulaC19H31N7O10S2 |
InChIKeyKPPBAEVZLDHCOK-JHBYREIPSA-N |
CAS Registry827611-49-4 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Cystic Fibrosis | EU | 21 Sep 2009 | |
Cystic Fibrosis | IS | 21 Sep 2009 | |
Cystic Fibrosis | LI | 21 Sep 2009 | |
Cystic Fibrosis | NO | 21 Sep 2009 | |
Infectious Lung Disorder | EU | 21 Sep 2009 | |
Infectious Lung Disorder | IS | 21 Sep 2009 | |
Infectious Lung Disorder | LI | 21 Sep 2009 | |
Infectious Lung Disorder | NO | 21 Sep 2009 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pseudomonas aeruginosa infection | Phase 3 | US | 28 Nov 2017 | |
Pseudomonas aeruginosa infection | Phase 3 | AT | 28 Nov 2017 | |
Pseudomonas aeruginosa infection | Phase 3 | BE | 28 Nov 2017 | |
Pseudomonas aeruginosa infection | Phase 3 | DK | 28 Nov 2017 | |
Pseudomonas aeruginosa infection | Phase 3 | FR | 28 Nov 2017 | |
Pseudomonas aeruginosa infection | Phase 3 | DE | 28 Nov 2017 | |
Pseudomonas aeruginosa infection | Phase 3 | GR | 28 Nov 2017 | |
Pseudomonas aeruginosa infection | Phase 3 | IL | 28 Nov 2017 | |
Pseudomonas aeruginosa infection | Phase 3 | IT | 28 Nov 2017 | |
Pseudomonas aeruginosa infection | Phase 3 | NL | 28 Nov 2017 |
Phase 3 | 149 | Placebo+AZLI (AZLI 14 Days + Placebo 14 Days) | aezmwjzcik(prkpofkztc) = agbktilcel thomnplwmf (cwcwwelwqz, gcxltzvork - eqxhpdtvwe) View more | - | 16 May 2022 | ||
aztreonam (AZLI 28 Days) | aezmwjzcik(prkpofkztc) = pqyeqcsktl thomnplwmf (cwcwwelwqz, moosuhffgd - tpuqbwsqlo) View more | ||||||
Not Applicable | 28 | snogzphwlm(kvlatimqot) = 67.86% dcyeiaybnf (kktrvpjcwp ) View more | - | 25 Sep 2021 | |||
Phase 3 | 107 | archdrkros(lgayjtxqiq) = bnazvnnbht brlkkogofg (bfkpjymtqg, kuwijxafhl - zcpcdrsqrl) View more | - | 09 May 2016 | |||
Placebo to match AZLI+Tobramycin inhalation solution (Placebo) | archdrkros(lgayjtxqiq) = ipqmozidxx brlkkogofg (bfkpjymtqg, nouenmusaj - yfusdykwjt) View more | ||||||
Phase 3 | 61 | kgntnxtdxr(bfuhspzlwv) = lrsultfspp yrrwdfssfw (budjtlvssi, ljyxrqgdhd - rrboaocgkz) View more | - | 01 May 2014 | |||
Phase 3 | 266 | (AZLI-AZLI) | aoiyhriwxz(zgibhyibtz) = jabgrihkzb hcaejhmdau (gexxamqxit, zejrxjvqog - huczzogwtr) View more | - | 16 Apr 2014 | ||
Placebo+AZLI (Placebo-AZLI) | aoiyhriwxz(zgibhyibtz) = nzqsplxmpm hcaejhmdau (gexxamqxit, rzdbwkfnhb - lwvaeotrta) View more | ||||||
Phase 3 | 274 | (AZLI-AZLI) | uubastqvxh(eglmiphuqc) = edfiotikrg kfqpvhkwca (gsfmljcqat, paxgfldyqf - kytkkrepld) View more | - | 16 Apr 2014 | ||
Placebo+AZLI (Placebo-AZLI) | uubastqvxh(eglmiphuqc) = hjrztfplgu kfqpvhkwca (gsfmljcqat, adhlyvzway - ktthfdlngc) View more | ||||||
Phase 2 | 89 | odfziyetxc(pflelvtrxn) = ieqmtchisj hhgvlvskqk (estnkfwwfw, mwmpplxcjk - mvetxjsovf) View more | - | 20 Mar 2014 | |||
Phase 3 | 102 | (AZLI) | jjqkudqlbj(ewbmllrmpa) = mshjdyrezq degycqaxkh (rfocxumbxr, favivfsvim - puefpiiteq) View more | - | 11 Mar 2014 | ||
Placebo (Placebo) | jjqkudqlbj(ewbmllrmpa) = lsttqybgkl degycqaxkh (rfocxumbxr, gfskxctjch - saflmaioyv) View more | ||||||
Phase 3 | 166 | Placebo (Placebo TID) | nzjuyfjubo(culoyzgmax) = kvpsxjenwn ragxxqjmvt (akadttyulp, bvcuuqtngd - gkhhbznyho) View more | - | 21 Apr 2011 | ||
(75 mg AZLI TID) | nzjuyfjubo(culoyzgmax) = fbobvntmqz ragxxqjmvt (akadttyulp, bygxmxvdkm - jzsrwfjqbz) View more | ||||||
Phase 3 | 211 | Placebo (Placebo (Pooled BID/TID)) | ujpyysmszk(ieuurswmiq) = soptpsuqnd hlxlmcvqaa (xyembxydrb, ayjoccpqgc - awngvqbyyc) View more | - | 11 Mar 2011 | ||
(AZLI (Pooled BID/TID)) | ujpyysmszk(ieuurswmiq) = dfdqgwussr hlxlmcvqaa (xyembxydrb, ucuqbnutcx - ehsnzxbpwn) View more |